Zobrazeno 1 - 10 of 10 pro vyhledávání: '"Perry Mohammed"'
2
Akademický článek
Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
Autor: Paula Munderi, Edwin Were, Anchalee Avihingsanon, Pascale A.M Mbida, Lerato Mohapi, Samba B. Moussa, Marjolein Jansen, Ceyhun Bicer, Perry Mohammed, Yvon van Delft
Publikováno v: Southern African Journal of HIV Medicine, Vol 20, Iss 1, Pp e1-e10 (2019)
Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtri
Externí odkaz: https://doaj.org/article/e52d18a06ca746ceaff0db06a7463e8c
Zobrazit plný text záznamu
3
Akademický článek
Quantifying pediatric patient need for second- and third-line HIV treatment: A tool for decision-making in resource-limited settings.
Autor: Perry Mohammed, Andrea Linden, Maura Reilly
Publikováno v: PLoS ONE, Vol 14, Iss 11, p e0224226 (2019)
As national HIV programs across the world mature and continue to scale up towards UNAIDS' 90-90-90 targets, it is increasingly important to accurately estimate HIV treatment needs in pediatric patient populations to prepare for anticipated increases
Externí odkaz: https://doaj.org/article/407821095c414fbc96fc2244511bece3
Zobrazit plný text záznamu
4
Akademický článek
Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
Autor: Anna Maria Geretti, Mathe Moeketsi, Ralph Demasi, Yvon van Delft, Perry Mohammed
Publikováno v: AIDS Research and Treatment, Vol 2015 (2015)
Background. An exploratory subanalysis of the ODIN trial was performed to evaluate the efficacy of darunavir/ritonavir (DRV/r) 800/100 mg OD versus 600/100 mg BID in patients who were NNRTI-experienced but PI-naïve. Methods. ODIN was a phase III, 48
Externí odkaz: https://doaj.org/article/c90bebc0cfe747638d2893a8d0204b57
Zobrazit plný text záznamu
5
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
Autor: Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu, Daniel Kiiza, John Kisembo, John Nsubuga, Max Okwero, Rhona Muyise, Claire Nasaazi, Dridah L. Nakiboneka, Josephine Namusanje, Theresa Najjuuko, Timothy Masaba, Timothy Serumaga, Adolf Alinaitwe, Allan Arinda, Angela Rweyora, Mary Goretti Kangah, Mariam Kasozi, Phionah Tukumushabe, Rogers Akunda, Shafic Makumbi, Sharif Musumba, Sula Myalo, John Ahuura, Annet Mary Namusisi, Daniel Kibirige, Francis Kiweewa, Habert Mabonga, Joseph Wandege, Josephine Nakakeeto, Sharon Namubiru, Winfred Nansalire, Abraham Mosigisi Siika, Charles Meja Kwobah, Chris Sande Mboya, Martha Mokeira Bisieri Mokaya, Mercy Jelagat Karoney, Priscilla Chepkorir Cheruiyot, Salinah Cherutich, Simon Wachira Njuguna, Viola Cherotich Kirui, Ennie Chidziva, Godfrey Musoro, James Hakim, Joyline Bhiri, Misheck Phiri, Shepherd Mudzingwa, Tadios Manyanga, Anchilla Mary Banegura, Betty Agwang, Brian Isaaya, Constantine Tumwine, Eva Laker A. Odongpiny, Nicholas Paton, Peter Senkungu, Yvonne Kamara, Mathius Amperiize, Elizabeth Allen, Charles Opondo, Perry Mohammed, Willemijn van Rein-van der Horst, Yvon Van Delft, Fafa Addo Boateng, Doreen Namara, Pontiano Kaleebu, Sylvia Ojoo, Tapiwanashe Bwakura, Milly Katana, Francois Venter, Sam Phiri, Sarah Walker
Publikováno v: The Lancet HIV. 9:e381-e393
WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to examine whether dolutegravir is non-inferior to d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9294a359496eae0df6d04748de07b343
https://doi.org/10.1016/s2352-3018(22)00092-3
Zobrazit plný text záznamu
6
Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
Autor: Samba B. Moussa, Perry Mohammed, Ceyhun Bicer, Yvon van Delft, Paula Munderi, Pascale A.M. Mbida, Edwin Were, Marjolein Jansen, Anchalee Avihingsanon, Lerato Mohapi
Publikováno v: Southern African Journal of HIV Medicine, Vol 20, Iss 1, Pp e1-e10 (2019)
Southern African Journal of HIV Medicine, Volume: 20, Issue: 1, Pages: 1-10, Published: 2019
Southern African Journal of HIV Medicine
Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e6c27f90703a98c384bdf112833e05
https://sajhivmed.org.za/index.php/hivmed/article/view/949
Zobrazit plný text záznamu
7
Quantifying pediatric patient need for second- and third-line HIV treatment: A tool for decision-making in resource-limited settings
Autor: Maura Reilly, Perry Mohammed, Andrea Linden
Publikováno v: PLoS ONE, Vol 14, Iss 11, p e0224226 (2019)
PLoS ONE
As national HIV programs across the world mature and continue to scale up towards UNAIDS' 90-90-90 targets, it is increasingly important to accurately estimate HIV treatment needs in pediatric patient populations to prepare for anticipated increases
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c9c07d273b5fe0268473431b0c7efc
https://doi.org/10.1371/journal.pone.0224226
Zobrazit plný text záznamu
8
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial
Autor: Thomas N. Kakuda, Ralph DeMasi, Perry Mohammed, Y van Delft
Publikováno v: HIV Medicine. 14:421-429
Objectives Etravirine is a substrate and inducer of cytochrome P450 (CYP) 3A and a substrate and inhibitor of CYP2C9 and CYPC2C19. Darunavir/ritonavir is a substrate and inhibitor of CYP3A. Artemether and lumefantrine are primarily metabolized by CYP
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f700d447db6c501273f682e1f197efcc
https://doi.org/10.1111/hiv.12019
Zobrazit plný text záznamu
9
Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
Autor: Mathe Moeketsi, Yvon van Delft, Anna Maria Geretti, Perry Mohammed, Ralph DeMasi
Publikováno v: AIDS Research and Treatment, Vol 2015 (2015)
AIDS Research and Treatment
Background. An exploratory subanalysis of the ODIN trial was performed to evaluate the efficacy of darunavir/ritonavir (DRV/r) 800/100 mg OD versus 600/100 mg BID in patients who were NNRTI-experienced but PI-naïve.Methods. ODIN was a phase III, 48-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b17639532cec4a376a748e38e1192a20
https://doaj.org/article/c90bebc0cfe747638d2893a8d0204b57
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje